745.35
-4.85 (-0.65%)
SENORES • 23 Oct, 2025 | 03:29 PM
Senores Pharmaceuticals Stock Performance
|
|
|
Senores Pharmaceuticals Company background
Founded in: 2017
Managing director: SWAPNIL JATINBHAI SHAH
Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the midmarket range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024.The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025.
Senores Pharmaceuticals Financial Highlights
Senores Pharmaceuticals reported a Q1FY26
revenue of ₹137.99 crore,
up 92.1% YoY,
with net profit increased
78.4% to ₹21.18 crore. For the full year FY2025–2026, revenue
reached ₹417.51 crore and profit touched at
₹58.34 crore. As of Sep '25, Senores Pharmaceuticals’s market capitalisation stood at ₹3,432.60 crores.
Shareholding as of Sep '25 shows promoters holding 45.8%, with FIIs at
4.3%, DIIs at 8.6%, and public at 41.3%.
Senores Pharmaceuticals Share Price Today
As of 23 Oct 2025, Senores Pharmaceuticals share price is ₹745.4. The stock opened at ₹754 and had closed at ₹750.2 the previous day. During today’s trading session, Senores Pharmaceuticals share price moved between ₹741.90 and ₹761.15, with an average price for the day of ₹751.52. Over the last 52 weeks, the stock has recorded a low of ₹435.25 and a high of ₹761.15. In terms of performance, Senores Pharmaceuticals share price has increased by 40.3% over the past six months and has increased by 24.38% over the last year.
Senores Pharmaceuticals Fundamental
Market Cap (in crs)
3,432.60
Face Value
10
Turnover (in lacs)
1,356.33
Key Metrics
Qtr Change %
New 52W High today
20.9
Dividend yield 1yr %
0
Senores Pharmaceuticals Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Senores Pharmaceuticals Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
137.99 Cr | 114.21 Cr | 103.02 Cr | 180.21 Cr | 0.8 Cr |
Senores Pharmaceuticals Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
417.51 Cr | 217.34 Cr | 39.02 Cr | 14.63 Cr |
Senores Pharmaceuticals Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
21.18 Cr | 17.97 Cr | 16.43 Cr | 23.83 Cr | 0.11 Cr |
Senores Pharmaceuticals Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
58.34 Cr | 32.71 Cr | 8.43 Cr | 0.99 Cr |
Senores Pharmaceuticals Result Highlights
Result Summary
-
Senores Pharmaceuticals Ltd reported a 35.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 17350.6%.
-
Its expenses for the quarter were down by 40.3% QoQ and up 16791.2% YoY.
-
The net profit decreased 35.2% QoQ and increased 19154.5% YoY.
-
The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 4.6 during Q1FY26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Senores Pharmaceuticals Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
745.35
Current Price
5Day EMA
737.20
10Day EMA
729.80
12Day EMA
727.70
20Day EMA
721.40
26Day EMA
717.50
50Day EMA
699.90
100Day EMA
663.70
200Day EMA
596.50
5Day SMA
736.10
10Day SMA
728.30
20Day SMA
716.30
30Day SMA
711.80
50Day SMA
708.10
100Day SMA
650.30
150Day SMA
613.00
200Day SMA
594.20
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 93859 Rs | 186905 Rs |
Week Rs | 98140 Rs | 172731 Rs |
Month Rs | 118573 Rs | 256475 Rs |
Resistance & Support
749.47
Pivot
Resistance
First Resistance
757.03
Second Resistance
768.72
Third Resistance
776.28
Support
First Support
737.78
Second support
730.22
Third Support
718.53
Relative Strength Index
58.60
Money Flow Index
68.12
MACD
10.19
MACD Signal
7.73
Average True Range
24.91
Average Directional Index
22.13
Rate of Change (21)
5.51
Rate of Change (125)
39.97
Senores Pharmaceuticals Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
344.35 | 3,453.23 | 298.8 | 504.25 | 349.65 | -3.07% | -7.33% | -4.63% | -22.04% | 64.29% | 0.03% | 56.55 | 41.10 | 5.75 | |
244.15 | 3,010.39 | 236.2 | 464.75 | 243.75 | 1.60% | -6.13% | -41.44% | -31.32% | -24.08% | 0.33% | 47.79 | 41.10 | 2.39 | |
95.22 | 2,794.97 | 57.5 | 126.66 | 95.15 | -2.89% | -17.03% | 42.14% | 21.55% | 33.34% | 0.84% | 26.48 | 41.10 | 1.65 | |
725.55 | 3,679.92 | 603.8 | 1997.4 | 729.75 | -0.42% | -3.78% | -10.56% | -43.33% | 107.63% | 0.00% | 38.53 | 41.10 | 2.93 | |
2,345.10 | 3,878.56 | 1835 | 2814 | 2,411.60 | 1.70% | -2.46% | 1.27% | -8.07% | 185.21% | 1.02% | 34.81 | 41.10 | 7.00 | |
467.20 | 3,289.36 | 455.55 | 937.95 | 464.45 | -0.45% | -5.56% | -27.70% | -42.37% | 22.69% | 0.00% | 24.14 | 41.10 | 1.33 |
Senores Pharmaceuticals Share Price FAQs
What is Share Price of Senores Pharmaceuticals ?
Senores Pharmaceuticals share price is ₹745.35 in NSE and ₹745.25 in BSE as on 23/10/2025.
How has Senores Pharmaceuticals shares performed in the past ?
Senores Pharmaceuticals share price in the past 1-year return was 0. The Senores Pharmaceuticals share hit a 1-year low of Rs. 435.25 and a 1-year high of Rs. 761.15.
What is the market cap of Senores Pharmaceuticals ?
The market cap of Senores Pharmaceuticals is Rs. 3432.6 Cr. as of 23/10/2025.
What is the current P/E ratio of Senores Pharmaceuticals ?
The PE ratios of Senores Pharmaceuticals is 0 as of 23/10/2025.
What is the current PB ratio of Senores Pharmaceuticals ?
The PB ratios of Senores Pharmaceuticals is 4.84 as of 23/10/2025
What is the Mutual Fund shareholding in Senores Pharmaceuticals ?
The Mutual Fund Shareholding in Senores Pharmaceuticals was 3.54% at the end of 23/10/2025.
How to buy Senores Pharmaceuticals shares?
You can easily buy Senores Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Senores Pharmaceuticals ?
The 52-week high and low of Senores Pharmaceuticals share price is ₹761.15 and ₹435.25 as of 23/10/2025.
What is the EPS of Senores Pharmaceuticals ?
The earnings per share (EPS) of Senores Pharmaceuticals stood at 4.6 during Q1FY26.
Please be aware that Senores Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.
Invest in Senores Pharmaceuticals